Abeona Therapeutics Inc (ABEO) Receives Consensus Rating of “Buy” from Brokerages
Abeona Therapeutics Inc (NASDAQ:ABEO) has earned an average recommendation of “Buy” from the eleven ratings firms that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $30.14.
A number of research analysts have recently commented on ABEO shares. Royal Bank of Canada reiterated a “buy” rating and set a $26.00 target price on shares of Abeona Therapeutics in a research report on Wednesday, January 24th. SunTrust Banks started coverage on Abeona Therapeutics in a research report on Wednesday, November 8th. They issued a “buy” rating and a $26.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $30.00 price target (up from $20.00) on shares of Abeona Therapeutics in a research report on Monday, October 16th. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Wednesday, November 22nd. Finally, Maxim Group set a $35.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 20th.
Abeona Therapeutics (NASDAQ:ABEO) traded down $1.48 during midday trading on Friday, hitting $14.08. The stock had a trading volume of 2,508,482 shares, compared to its average volume of 1,061,003. The company has a market cap of $727.35, a P/E ratio of -21.33 and a beta of 1.23. Abeona Therapeutics has a 52-week low of $4.55 and a 52-week high of $22.75.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Virtus Fund Advisers LLC bought a new stake in Abeona Therapeutics in the fourth quarter worth $346,000. Virtu Financial LLC bought a new stake in Abeona Therapeutics in the fourth quarter worth $246,000. BlackRock Inc. lifted its position in Abeona Therapeutics by 15.1% in the fourth quarter. BlackRock Inc. now owns 1,868,378 shares of the biopharmaceutical company’s stock worth $29,614,000 after buying an additional 245,217 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Abeona Therapeutics by 89.8% in the fourth quarter. Bank of New York Mellon Corp now owns 195,474 shares of the biopharmaceutical company’s stock worth $3,097,000 after buying an additional 92,465 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its position in Abeona Therapeutics by 32.1% in the fourth quarter. Wells Fargo & Company MN now owns 46,529 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 11,311 shares during the last quarter. Institutional investors own 41.97% of the company’s stock.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.